Scarica l'app Stockscreener
4.32
0.70%
0.03
Dopo l'orario di chiusura:
4.32
Precedente Chiudi:
$4.29
Aprire:
$4.35
Volume 24 ore:
49,202
Relative Volume:
0.78
Capitalizzazione di mercato:
$82.44M
Reddito:
-
Utile/perdita netta:
$-34.17M
Rapporto P/E:
-1.9085
EPS:
-2.2635
Flusso di cassa netto:
$-47.63M
1 W Prestazione:
-1.14%
1M Prestazione:
+2.37%
6M Prestazione:
+29.54%
1 anno Prestazione:
+57.09%
Intervallo 1D:
$4.26
$4.47
Intervallo di 1 settimana:
$4.03
$4.47
Portata 52W:
$2.30
$5.12
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.32 | 81.87M | 0 | -34.17M | -47.63M | -2.2635 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Iniziato | Roth Capital | Buy |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-09-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-07-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Iniziato | Alliance Global Partners | Buy |
| 2020-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2020-07-21 | Iniziato | Barclays | Overweight |
| 2020-07-21 | Iniziato | Raymond James | Outperform |
Mostra tutto
Polypid Ltd Borsa (PYPD) Ultime notizie
PolyPid (PYPD) COO details stock option and share holdings - Stock Titan
PolyPid (PYPD) director Dror-Darwish Nir lists six vested option grants - Stock Titan
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
PolyPid (PYPD) CFO details extensive employee stock option awards - Stock Titan
PolyPid (PYPD) director Barenholz discloses shares and multiple option grants - Stock Titan
PolyPid (PYPD) director Joseph BenAmram reports initial stock option grants - Stock Titan
Pullback Watch: Whats the beta of PolyPid Ltd stock2026 Risk Factors & Verified Short-Term Trading Plans - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Axsome Therapeutics (AXSM) - The Globe and Mail
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
PolyPid (PYPD) director discloses stock options on 17,456 shares - Stock Titan
PolyPid (PYPD) director details shares and vested stock options - Stock Titan
PolyPid (PYPD) CEO details stock and option holdings in Form 3 - Stock Titan
PolyPid (PYPD) deputy CEO discloses extensive employee stock options - Stock Titan
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - TipRanks
Is PolyPid Ltd likely to announce a buybackEarnings Growth Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
PolyPid granted $4.3M waiver from FDA for D-Plex application - TipRanks
PolyPid receives $4.3M FDA fee waiver for D-PLEX100 application - Investing.com
Polypid receives PDUFA fee waiver from FDA for D-Plex100's new drug application - marketscreener.com
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application - GlobeNewswire
PolyPid Ltd. (NASDAQ:PYPD) Sees Large Drop in Short Interest - MarketBeat
PolyPid Ltd Stock (ISIN: US70450B1035) Surges on Analyst Optimism: 260% Upside Forecast Signals Majo - AD HOC NEWS
Wall Street Zen Upgrades PolyPid (NASDAQ:PYPD) to Hold - MarketBeat
PolyPid at Citizens Life Sciences: Strategic Moves and Market Expansion - Investing.com India
PolyPid at Citizens Life Sciences: Strategic Moves and Market Expansion By Investing.com - Investing.com Australia
PYPD: NDA submission for D-PLEX₁₀₀ is imminent, backed by strong Phase 3 efficacy data - TradingView
How PolyPid Ltd. stock performs in stagflation2026 Short Interest & Stepwise Trade Execution Plans - Naître et grandir
PYPD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PYPD SEC FilingsPolypid Ltd. 10-K, 10-Q, 8-K Forms - Stock Titan
PolyPid (NASDAQ:PYPD) Downgraded by Wall Street Zen to "Sell" - MarketBeat
PYPD PE Ratio & Valuation, Is PYPD Overvalued - Intellectia AI
PolyPid Announces Participation in Upcoming Investor Conferences - Bitget
PolyPid Ltd. Auditor Raises 'Going Concern' Doubt - marketscreener.com
PolyPid Ltd. (NASDAQ:PYPD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is PolyPid Ltd. stock forming a triangle patternJuly 2025 Recap & Daily Profit Maximizing Trade Tips - mfd.ru
Does PolyPid Ltd. have high return on assetsMarket Sentiment Report & Long-Term Growth Portfolio Plans - mfd.ru
Is PolyPid Ltd. stock technically oversoldJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - mfd.ru
Polypid targets rolling NDA submission for D-PLEX100 by end of Q1 2026 amid advanced US partnership talks - MSN
Aug Decliners: Is PolyPid Ltd likely to announce a buyback2025 Technical Patterns & Fast Gain Swing Trade Alerts - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 44.8% in January - MarketBeat
Research Analysts Issue Forecasts for PolyPid Q1 Earnings - Defense World
HC Wainwright Predicts PolyPid's Q1 Earnings (NASDAQ:PYPD) - MarketBeat
When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit? - Yahoo Finance
PolyPid Q4 Earnings Call Highlights - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 Earnings Call Transcript - Insider Monkey
Is PolyPid Ltd. likely to announce a buybackJuly 2025 Recap & Low Risk High Win Rate Picks - mfd.ru
FY2028 Earnings Forecast for PolyPid Issued By HC Wainwright - MarketBeat
PolyPid Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
PolyPid Earnings Call Flags Big 2026 Catalyst - TipRanks
PolyPid (PYPD) Analyst Rating Reiteration by HC Wainwright | PYP - GuruFocus
PolyPid (NASDAQ:PYPD) Earns Buy Rating from HC Wainwright - MarketBeat
PolyPid (NASDAQ:PYPD) Releases Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Polypid Ltd Azioni (PYPD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.04%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):